NCT03722420 2024-10-28Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Il-Yang Pharm. Co., Ltd.Phase 3 Active not recruiting238 enrolled